Antimalarial Drug Resistance: A Threat to Malaria Elimination

Increasing antimalarial drug resistance once again threatens effective antimalarial drug treatment, malaria control, and elimination. Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinin...

Full description

Saved in:
Bibliographic Details
Published in:Cold Spring Harbor perspectives in medicine 2017-07, Vol.7 (7), p.a025619
Main Authors: Menard, Didier, Dondorp, Arjen
Format: Article
Language:English
Subjects:
Antigens, Bacterial
Antigens, Bacterial - genetics
Antigens, Surface
Antigens, Surface - genetics
Antimalarials
Antimalarials - pharmacology
Artemisinins
Artemisinins - pharmacology
Drug Resistance
Drug Resistance - genetics
Drug Therapy, Combination
Human health and pathology
Humans
Infectious diseases
Life Sciences
Malaria, Falciparum
Malaria, Falciparum - drug therapy
Malaria, Vivax
Malaria, Vivax - drug therapy
Plasmodium
Plasmodium - drug effects
Plasmodium - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c439t-799b5f9d2728c4e56b853cabc0f473f1019d15c24ed1a45698d5f4cbabb459ca3
cites cdi_FETCH-LOGICAL-c439t-799b5f9d2728c4e56b853cabc0f473f1019d15c24ed1a45698d5f4cbabb459ca3
container_end_page
container_issue 7
container_start_page a025619
container_title Cold Spring Harbor perspectives in medicine
container_volume 7
creator Menard, Didier
Dondorp, Arjen
description Increasing antimalarial drug resistance once again threatens effective antimalarial drug treatment, malaria control, and elimination. Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinins has emerged in the Greater Mekong Subregion. Concomitant emergence of partner drug resistance is now causing high ACT treatment failure rates in several areas. Genetic markers for artemisinin resistance and several of the partner drugs have been established, greatly facilitating surveillance. Single point mutations in the gene coding for the Kelch propeller domain of the K13 protein strongly correlate with artemisinin resistance. Novel regimens and strategies using existing antimalarial drugs will be needed until novel compounds can be deployed. Elimination of artemisinin resistance will imply elimination of all falciparum malaria from the same areas. In vivax malaria, chloroquine resistance is an increasing problem.
doi_str_mv 10.1101/cshperspect.a025619
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5495053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1877526916</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-799b5f9d2728c4e56b853cabc0f473f1019d15c24ed1a45698d5f4cbabb459ca3</originalsourceid><addsrcrecordid>eNpdUVFLwzAQDqK4MfcLBOmjPnQmadI0gkKZ0wkTQeZzSNN0i3TtTNKB_96MzTG9lxx33_fdXT4ALhEcIQTRrXLLtbZurZUfSYhpivgJ6GPCcEwJwqchR5TFiGDcA0PnPmEImqYZg-eghzOccUyyPrjPG29WspbWyDp6tN0ietfOOC8bpe-iPJovrZY-8m30ukNFk9qsTCO9aZsLcFbJ2unh_h2Aj6fJfDyNZ2_PL-N8FiuScB8zzgta8RIznCmiaVpkNFGyULAiLKnCPbxEVGGiSyQJTXlW0oqoQhYFoVzJZAAedrrrrljpUunGW1mLtQ2r22_RSiP-dhqzFIt2IyjhFNIkCNzsBJb_aNN8Jra18IWUJ5BvUMBe74fZ9qvTzouVcUrXtWx02zmBMsYoTjlKAzTZQZVtnbO6OmgjKLY-iSOfxN6nwLo6vubA-XUl-QEFypG0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1877526916</pqid></control><display><type>article</type><title>Antimalarial Drug Resistance: A Threat to Malaria Elimination</title><source>PubMed Central</source><creator>Menard, Didier ; Dondorp, Arjen</creator><creatorcontrib>Menard, Didier ; Dondorp, Arjen</creatorcontrib><description>Increasing antimalarial drug resistance once again threatens effective antimalarial drug treatment, malaria control, and elimination. Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinins has emerged in the Greater Mekong Subregion. Concomitant emergence of partner drug resistance is now causing high ACT treatment failure rates in several areas. Genetic markers for artemisinin resistance and several of the partner drugs have been established, greatly facilitating surveillance. Single point mutations in the gene coding for the Kelch propeller domain of the K13 protein strongly correlate with artemisinin resistance. Novel regimens and strategies using existing antimalarial drugs will be needed until novel compounds can be deployed. Elimination of artemisinin resistance will imply elimination of all falciparum malaria from the same areas. In vivax malaria, chloroquine resistance is an increasing problem.</description><identifier>ISSN: 2157-1422</identifier><identifier>EISSN: 2472-5412</identifier><identifier>DOI: 10.1101/cshperspect.a025619</identifier><identifier>PMID: 28289248</identifier><language>eng</language><publisher>United States: Cold Spring Harbor Laboratory Press</publisher><subject>Antigens, Bacterial ; Antigens, Bacterial - genetics ; Antigens, Surface ; Antigens, Surface - genetics ; Antimalarials ; Antimalarials - pharmacology ; Artemisinins ; Artemisinins - pharmacology ; Drug Resistance ; Drug Resistance - genetics ; Drug Therapy, Combination ; Human health and pathology ; Humans ; Infectious diseases ; Life Sciences ; Malaria, Falciparum ; Malaria, Falciparum - drug therapy ; Malaria, Vivax ; Malaria, Vivax - drug therapy ; Plasmodium ; Plasmodium - drug effects ; Plasmodium - genetics</subject><ispartof>Cold Spring Harbor perspectives in medicine, 2017-07, Vol.7 (7), p.a025619</ispartof><rights>Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-799b5f9d2728c4e56b853cabc0f473f1019d15c24ed1a45698d5f4cbabb459ca3</citedby><cites>FETCH-LOGICAL-c439t-799b5f9d2728c4e56b853cabc0f473f1019d15c24ed1a45698d5f4cbabb459ca3</cites><orcidid>0000-0003-1357-4495</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495053/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495053/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28289248$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02559309$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Menard, Didier</creatorcontrib><creatorcontrib>Dondorp, Arjen</creatorcontrib><title>Antimalarial Drug Resistance: A Threat to Malaria Elimination</title><title>Cold Spring Harbor perspectives in medicine</title><addtitle>Cold Spring Harb Perspect Med</addtitle><description>Increasing antimalarial drug resistance once again threatens effective antimalarial drug treatment, malaria control, and elimination. Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinins has emerged in the Greater Mekong Subregion. Concomitant emergence of partner drug resistance is now causing high ACT treatment failure rates in several areas. Genetic markers for artemisinin resistance and several of the partner drugs have been established, greatly facilitating surveillance. Single point mutations in the gene coding for the Kelch propeller domain of the K13 protein strongly correlate with artemisinin resistance. Novel regimens and strategies using existing antimalarial drugs will be needed until novel compounds can be deployed. Elimination of artemisinin resistance will imply elimination of all falciparum malaria from the same areas. In vivax malaria, chloroquine resistance is an increasing problem.</description><subject>Antigens, Bacterial</subject><subject>Antigens, Bacterial - genetics</subject><subject>Antigens, Surface</subject><subject>Antigens, Surface - genetics</subject><subject>Antimalarials</subject><subject>Antimalarials - pharmacology</subject><subject>Artemisinins</subject><subject>Artemisinins - pharmacology</subject><subject>Drug Resistance</subject><subject>Drug Resistance - genetics</subject><subject>Drug Therapy, Combination</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Life Sciences</subject><subject>Malaria, Falciparum</subject><subject>Malaria, Falciparum - drug therapy</subject><subject>Malaria, Vivax</subject><subject>Malaria, Vivax - drug therapy</subject><subject>Plasmodium</subject><subject>Plasmodium - drug effects</subject><subject>Plasmodium - genetics</subject><issn>2157-1422</issn><issn>2472-5412</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpdUVFLwzAQDqK4MfcLBOmjPnQmadI0gkKZ0wkTQeZzSNN0i3TtTNKB_96MzTG9lxx33_fdXT4ALhEcIQTRrXLLtbZurZUfSYhpivgJ6GPCcEwJwqchR5TFiGDcA0PnPmEImqYZg-eghzOccUyyPrjPG29WspbWyDp6tN0ietfOOC8bpe-iPJovrZY-8m30ukNFk9qsTCO9aZsLcFbJ2unh_h2Aj6fJfDyNZ2_PL-N8FiuScB8zzgta8RIznCmiaVpkNFGyULAiLKnCPbxEVGGiSyQJTXlW0oqoQhYFoVzJZAAedrrrrljpUunGW1mLtQ2r22_RSiP-dhqzFIt2IyjhFNIkCNzsBJb_aNN8Jra18IWUJ5BvUMBe74fZ9qvTzouVcUrXtWx02zmBMsYoTjlKAzTZQZVtnbO6OmgjKLY-iSOfxN6nwLo6vubA-XUl-QEFypG0</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Menard, Didier</creator><creator>Dondorp, Arjen</creator><general>Cold Spring Harbor Laboratory Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1357-4495</orcidid></search><sort><creationdate>20170701</creationdate><title>Antimalarial Drug Resistance: A Threat to Malaria Elimination</title><author>Menard, Didier ; Dondorp, Arjen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-799b5f9d2728c4e56b853cabc0f473f1019d15c24ed1a45698d5f4cbabb459ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antigens, Bacterial</topic><topic>Antigens, Bacterial - genetics</topic><topic>Antigens, Surface</topic><topic>Antigens, Surface - genetics</topic><topic>Antimalarials</topic><topic>Antimalarials - pharmacology</topic><topic>Artemisinins</topic><topic>Artemisinins - pharmacology</topic><topic>Drug Resistance</topic><topic>Drug Resistance - genetics</topic><topic>Drug Therapy, Combination</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Life Sciences</topic><topic>Malaria, Falciparum</topic><topic>Malaria, Falciparum - drug therapy</topic><topic>Malaria, Vivax</topic><topic>Malaria, Vivax - drug therapy</topic><topic>Plasmodium</topic><topic>Plasmodium - drug effects</topic><topic>Plasmodium - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Menard, Didier</creatorcontrib><creatorcontrib>Dondorp, Arjen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cold Spring Harbor perspectives in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Menard, Didier</au><au>Dondorp, Arjen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antimalarial Drug Resistance: A Threat to Malaria Elimination</atitle><jtitle>Cold Spring Harbor perspectives in medicine</jtitle><addtitle>Cold Spring Harb Perspect Med</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>7</volume><issue>7</issue><spage>a025619</spage><pages>a025619-</pages><issn>2157-1422</issn><eissn>2472-5412</eissn><abstract>Increasing antimalarial drug resistance once again threatens effective antimalarial drug treatment, malaria control, and elimination. Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinins has emerged in the Greater Mekong Subregion. Concomitant emergence of partner drug resistance is now causing high ACT treatment failure rates in several areas. Genetic markers for artemisinin resistance and several of the partner drugs have been established, greatly facilitating surveillance. Single point mutations in the gene coding for the Kelch propeller domain of the K13 protein strongly correlate with artemisinin resistance. Novel regimens and strategies using existing antimalarial drugs will be needed until novel compounds can be deployed. Elimination of artemisinin resistance will imply elimination of all falciparum malaria from the same areas. In vivax malaria, chloroquine resistance is an increasing problem.</abstract><cop>United States</cop><pub>Cold Spring Harbor Laboratory Press</pub><pmid>28289248</pmid><doi>10.1101/cshperspect.a025619</doi><orcidid>https://orcid.org/0000-0003-1357-4495</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2157-1422
ispartof Cold Spring Harbor perspectives in medicine, 2017-07, Vol.7 (7), p.a025619
issn 2157-1422
2472-5412
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5495053
source PubMed Central
subjects Antigens, Bacterial
Antigens, Bacterial - genetics
Antigens, Surface
Antigens, Surface - genetics
Antimalarials
Antimalarials - pharmacology
Artemisinins
Artemisinins - pharmacology
Drug Resistance
Drug Resistance - genetics
Drug Therapy, Combination
Human health and pathology
Humans
Infectious diseases
Life Sciences
Malaria, Falciparum
Malaria, Falciparum - drug therapy
Malaria, Vivax
Malaria, Vivax - drug therapy
Plasmodium
Plasmodium - drug effects
Plasmodium - genetics
title Antimalarial Drug Resistance: A Threat to Malaria Elimination
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A42%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antimalarial%20Drug%20Resistance:%20A%20Threat%20to%20Malaria%20Elimination&rft.jtitle=Cold%20Spring%20Harbor%20perspectives%20in%20medicine&rft.au=Menard,%20Didier&rft.date=2017-07-01&rft.volume=7&rft.issue=7&rft.spage=a025619&rft.pages=a025619-&rft.issn=2157-1422&rft.eissn=2472-5412&rft_id=info:doi/10.1101/cshperspect.a025619&rft_dat=%3Cproquest_pubme%3E1877526916%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c439t-799b5f9d2728c4e56b853cabc0f473f1019d15c24ed1a45698d5f4cbabb459ca3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1877526916&rft_id=info:pmid/28289248&rfr_iscdi=true